May is Mental Health Awareness Month and with 1 in 5 American adults (23.1% of the population) living with mental illness, ...

Myriad Genetics' growth potential lies in its innovative products, strong financials, and expanding market opportunities.

Fear of side effects prevents more than half of those diagnosed with treatable depression and anxiety from taking medications ...

Members of the Utah delegation to the 119th Congress here have joined forces to preserve the Research Park at the University ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) ...

In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market.

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

About the Study The study analyzed a dataset generated by linking more than a half million de-identified patients who received the GeneSight test to administrative insurance claim ...

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...